Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) See


Versions (3) ▾
  1. 11/18/11
  2. 3/26/14
  3. 9/17/21
Uploaded on:

September 17, 2021

No DOI assigned. To request one please log in.
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility DRKS00004052 NCT00661609 Bladder Cancer

Eligibility Advanced Bladder Cancer NCT00661609

Inclusion criteria
Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra)
Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy
Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting
Ambulatory and capable of all selfcare more than 50% of waking hours
Exclusion criteria
Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication, 6 weeks if prior systemic mitomycin, nitrosourea, or suramin.
Inadequate bone marrow reserve
Inadequate liver function in the presence of liver metastases
Impaired renal function

Similar models